Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the leading causes of blindness globally. Retinal neuronal abnormalities occur in the early stage in DR. Therefore, maintaining retinal neuronal activity in DR may prevent vision loss. Previously, pemafibrate, a novel selective peroxisome proliferator-activated re...

Full description

Bibliographic Details
Main Authors:	Yohei Tomita, Deokho Lee, Yukihiro Miwa, Xiaoyan Jiang, Masayuki Ohta, Kazuo Tsubota, Toshihide Kurihara
Format:	Article
Language:	English
Published:	MDPI AG 2020-08-01
Series:	International Journal of Molecular Sciences
Subjects:	diabetes retinopathy (DR) electroretinography (ERG) fibroblast growth factor21 (FGF21) pemafibrate streptozotocin (STZ) synaptophysin
Online Access:	https://www.mdpi.com/1422-0067/21/17/6243

Similar Items

Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion
by: Deokho Lee, et al.
Published: (2021-08-01)

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
by: Deokho Lee, et al.
Published: (2023-01-01)

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
by: Koutaro Yokote, et al.
Published: (2021-05-01)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
by: Zhe Zhang, et al.
Published: (2022-07-01)

Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia
by: Deokho Lee, et al.
Published: (2021-03-01)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
by: Yohei Tomita, et al.
Published: (2020-10-01)

Electroretinography (A Review)
by: Balicka A., et al.
Published: (2016-03-01)

Electrical activity in rat retina in a streptozotocin-induced diabetes model
by: Ekaterina M. Klochihina, et al.
Published: (2018-11-01)

Streptozotocin - an antibiotic used to induce diabetes on experimental animals
by: Dagna Siedlecka, et al.
Published: (2020-09-01)

Retinal dysfunction induced in a mouse model of unilateral common carotid artery occlusion
by: Deokho Lee, et al.
Published: (2021-06-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
by: Naofumi Amioka, et al.
Published: (2022-06-01)

Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
by: Yohei Tomita, et al.
Published: (2021-10-01)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
by: Hiroshi Nomoto, et al.
Published: (2023-10-01)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
by: Shigeki Kitamura, et al.
Published: (2023-09-01)

Rat Diabetic Blood Glucose Level Profile with Stratified Dose Streptozotocin (SD-STZ) and Multi Low Dose Streptozotocin (MLD-STZ) Induction Methods
by: Nuzulul Hikmah, et al.
Published: (2015-01-01)

Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice
by: Jia Nuo Feng, et al.
Published: (2023-03-01)

Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
by: Xiaoxue Long, et al.
Published: (2021-12-01)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
by: Shizuya Yamashita, et al.
Published: (2023-05-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
by: Ryosuke Sugimoto, et al.
Published: (2023-02-01)

The role of FGF21 and its analogs on liver associated diseases
by: Kimia Falamarzi, et al.
Published: (2022-11-01)

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
by: Deokho Lee, et al.
Published: (2023-01-01)

Multifocal Electroretinography in Diabetic Patients without Retinopathy
by: Özgür Balta, et al.
Published: (2018-12-01)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
by: Hiroshi Nomoto, et al.
Published: (2023-06-01)

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
by: Kazufumi Dohmen, et al.
Published: (2021-10-01)

OculusGraphy: Signal Analysis of the Electroretinogram in a Rabbit Model of Endophthalmitis Using Discrete and Continuous Wavelet Transforms
by: Aleksei Zhdanov, et al.
Published: (2023-06-01)

A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
by: Iroz, Alison, et al.
Published: (2017)

LPS infusion suppresses serum FGF21 levels in healthy adult volunteers
by: Esben S Lauritzen, et al.
Published: (2017-02-01)

Can allopurinol improve retinopathy in diabetic rats? Oxidative stress or uric acid; which one is the culprit?
by: Mohsen Goharinia, et al.
Published: (2017-01-01)

Effects of Smoothing and Adaptive Filtering in Multifocal Electroretinography (mfERG)
by: Christopher Patrick Long, et al.
Published: (2023-08-01)

Paraneoplastic retinopathies
by: Marko Hawlina, et al.
Published: (2005-10-01)

FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice
by: Zhongjie Fu, et al.
Published: (2017-02-01)

Differences in brain activity between normal and diabetic rats under isoflurane anesthesia: a resting-state functional MRI study
by: Sheng-Min Huang, et al.
Published: (2022-08-01)

New spectral templates for rhodopsin and porphyropsin visual pigments
by: Gačić Zoran, et al.
Published: (2019-01-01)

FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD
by: Zhiyuan Wang, et al.
Published: (2023-12-01)

Physical Exercise-Induced FGF-21 to Fight Obesity: An Update Review
by: Bruno Vecchiatto, et al.
Published: (2022-11-01)

The elevation of fibroblast growth factor 21 is associated with generalized periodontitis in patients with treated metabolic syndrome
by: Teerat Sawangpanyangkura, et al.
Published: (2022-12-01)

Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21–AMPK pathway in mice fed a high fat diet
by: Yuanyuan Zhang, et al.
Published: (2022-04-01)

Increased fructose consumption has sex‐specific effects on fibroblast growth factor 21 levels in humans
by: M. Rodgers, et al.
Published: (2019-10-01)

Effect of glucocorticoid on the retinal neurons of diabetes mellitus rats
by: Wen-Qiang Liu, et al.
Published: (2017-03-01)